

RSV disease burden in older adults

Xiao Li

Centre for Health Economics Research & Modelling Infectious Diseases (CHERMID)

20th April 2023,

Antwerp, Belgium


Summary

- Landscape of the RSV vaccines
- Systematic reviews of RSV Disease burden in older adults
- A RESCEU prospective study in European adults




RSV Vaccine and mAb Snapshot

TARGET INDICATION: P = PEDIATRIC M = MATERNAL E = ELDERLY



https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/

Global disease burden (systematic reviews)



Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries

Jonathan S. Nguyen-Van-Tam, Maureen O'Leary, Emily T. Martin, Esther Heijnen, Benoit Callendret, Roman Fleischhackl, Christy Comeaux, Thao Mai Phuong Tran, Karin Weber European Respiratory Review 2022 31: 220105; DOI: 10.1183/16000617.0105-2022



Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic **Review and Modelling Study**

You Li 🗁, Durga Kulkarni, Elizabeth Begier, Pia Wahi-Singh, Bhanu Wahi-Singh, Bradford Gessner & Harish Nair

Infectious Diseases and Therapy (2023) Cite this article



RSV disease burdens in two systematic reviews

Savic 2022 Overall (point estimates, 95% CI)	RSV-ARI Attack rate 1.62% (0.84-3.08)	RSV hospitalizations Hospitalization rate 0.15% (0.09-0.22)	RSV in-hospital deaths hCFR 7.13% (5.40-9.36)
	RSV – ARI incidence		RSV – case fatality proportion
Nguyen-Van- Tam 2022	 Annual studies: 4.66% (3.34-6.48) Seasonal studies: 7.80% (5.77-10.45%) 		 Overall: 8.8% (5.54-11.94%) High-risk group: 9.88% (6.66-14.43) Annual studies: 7.03% (5.18-9.48%) Seasonal studies: 7.69% (6.23-9.46%)



Comparison among the systematic reviews

	Age	Adjusted for under- ascertainment	Estimates hospitalisation rate (95% CI) per 100,000	Key study characteristics for comparison	
Shi et al 2020	≥65 years	No	100 (50-210)	A wide range of case definitions allowed	
Savic 2022	≥60 years	No	145(94-224)	Hospitalisation attack rate (rather than annual hospitalisation rate)	
McLaughlin et al 2022	≥65 years	No	178 (152-204)	Limited to the USA; including all RSV-associated hospitalisations; not excluding modelling studies	
McLaughlin et al 2022	≥65 years	Partly	267 (228-306)	Limited to the USA; including all RSV-associated hospitalisations; not excluding modelling studies; limited to studies using PCR or serology	
Li et al 2023	≥65 years	No	157 (98-252)	Strictly limited to ARI	
Li et al 2023	≥65 years	Yes	347 (203-595)	Strictly limited to ARI	

After adjusting for diagnostic testing characteristics related to clinical specimens and testing approaches \rightarrow An estimated 2.2-fold higher disease burden

The older adult (aged ≥60 years) study



Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study

Koos Korsten, Niels Adriaenssens, Samuel Coenen, Christopher Butler, Behnaz Ravanfar, Heather Rutter, Julie Allen, Ann Falsey, Jean-Yves Pirçon, Olivier Gruselle, Vincent Pavot, Charlotte Vernhes, Sunita Balla-Jhagjhoorsingh, Deniz Öner, Gabriela Ispas, Jeroen Aerssens, Vivek Shinde, Theo Verheij, Louis Bont, Joanne Wildenbeest on behalf of the RESCEU investigators European Respiratory Journal 2021 57: 2002688; **DOI:** 10.1183/13993003.02688-2020



Volume 226, Issue Supplement_1 1 August 2022

Article Contents

JOURNAL ARTICLE

Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults

Zhuxin Mao ☎, Xiao Li, Koos Korsten, Louis Bont, Christopher Butler, Joanne Wildenbeest, Samuel Coenen, Niel Hens, Joke Bilcke, Philippe Beutels ... Show more

Author Notes

The Journal of Infectious Diseases, Volume 226, Issue Supplement_1, 1 August 2022,

Prospective, observational, cohort study (N=1040)

• 3 European countries & 2 seasons

Objective:

- Estimate average costs and Health-related quality-of-life in older adults (≥60 years) with RSV infection
- Compared RSV to influenza-related costs and HRQoL



Cost per RSV and influenza (non-hospital) episode

	RSV (N=36)				Influenza (N=59)			
Perspective	Patient	Healthcare provider	Healthcare payer	Societal	Patient		Healthcare payer	Societal
Health care visits	0.78 [0] (0 - 0)	11.74 [0] (0 - 23.06)	12.52 [0] (0 - 27.06)		1.76 [0] (0 - 2.00)	21.67 [23.06] (0 - 35.00)	23.44 [27.06] (0 – 35.00)	
Medication	10.97 [2.7] (0 - 12.2)	2.88 [0] (0 - 0.55)	13.85 [5.54] (0 - 18.39)		14.44 [3.12] (0 - 17.63)	4.62 [0] (0 - 4.1)	19.06 [7.80] (0.97 - 24.83)	
Direct cost	11.74 [3.42] (0 - 12.2)	14.62 [0] (0 - 23.22)	26.37 [5.54] (0 - 47.31)		16.2 [4.00] (0.21 - 22.9)	26.29 [23.06] (0 - 40)	42.49 [35.98] (3.34 - 66.7)	
Productivity loss				4.38 [0] (0 - 0)				32.07 [0] (0 - 0)
Total costs				30.75 [5.54] (0 - 50.02)				74.56 [36.90] (5.42 - 73.53)


The mean [median] and (1st – 3rd quartile) costs per RSV and influenza episode (2020 € value)

Findings:

- The mean costs were lower per RSV episode vs. influenza episode, but interquartile ranges overlapped largely.
- Due to small sample size, no formal statistical comparisons were made.
- Extensive subgroup analyses were performed (e.g. by medically attendance, by country)

Health-related quality-of-life

RSV episodes had higher utility values than influenza episodes at each time point, in other words, quality-of-life impact of RSV seems smaller than for influenza



RSV 🔄 Influenza



Discussion

- The first RSV older adults vaccine is likely to be approved by FDA in Q2 2023
- The burden of RSV disease among older adults is still unclear, and almost unknown in adults including pregnant women
- In order to make a more informed decision, collecting cost and healthrelated quality-of-life studies are crucial
- Cost-effectiveness of RSV vaccines in older adults need to be carefully evaluated



